Twist Bioscience (NASDAQ:TWST) CAO Robert Werner Sells 1,016 Shares

Twist Bioscience Corporation (NASDAQ:TWST) CAO Robert Werner sold 1,016 shares of the firm’s stock in a transaction dated Thursday, October 30th. The shares were sold at an average price of $31.44, for a total value of $31,943.04. Following the completion of the sale, the chief accounting officer directly owned 51,030 shares in the company, valued at approximately $1,604,383.20. This represents a 1.95% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink.

Twist Bioscience Stock Performance

NASDAQ TWST traded down $1.32 during midday trading on Monday, hitting $31.57. The company had a trading volume of 1,224,978 shares, compared to its average volume of 1,305,728. Twist Bioscience Corporation has a fifty-two week low of $24.07 and a fifty-two week high of $55.33. The stock has a market cap of $1.91 billion, a price-to-earnings ratio of -21.77 and a beta of 2.38. The firm has a fifty day simple moving average of $28.97 and a two-hundred day simple moving average of $31.82. The company has a quick ratio of 3.60, a current ratio of 3.90 and a debt-to-equity ratio of 0.03.

Twist Bioscience (NASDAQ:TWST) last released its quarterly earnings data on Monday, August 4th. The company reported ($0.47) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.54) by $0.07. Twist Bioscience had a negative return on equity of 29.03% and a negative net margin of 23.51%.The company had revenue of $96.06 million for the quarter, compared to the consensus estimate of $95.52 million. Equities analysts forecast that Twist Bioscience Corporation will post -2.12 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Twist Bioscience

A number of institutional investors have recently bought and sold shares of TWST. Mirae Asset Global Investments Co. Ltd. increased its holdings in shares of Twist Bioscience by 15.0% in the second quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,315 shares of the company’s stock valued at $85,000 after purchasing an additional 302 shares during the last quarter. GAMMA Investing LLC grew its stake in Twist Bioscience by 68.1% during the first quarter. GAMMA Investing LLC now owns 748 shares of the company’s stock worth $29,000 after buying an additional 303 shares in the last quarter. D.A. Davidson & CO. boosted its position in shares of Twist Bioscience by 1.5% during the 2nd quarter. D.A. Davidson & CO. now owns 23,062 shares of the company’s stock worth $848,000 after acquiring an additional 352 shares in the last quarter. California State Teachers Retirement System boosted its stake in shares of Twist Bioscience by 0.8% in the 2nd quarter. California State Teachers Retirement System now owns 54,187 shares of the company’s stock valued at $1,994,000 after purchasing an additional 442 shares in the last quarter. Finally, Vanguard Personalized Indexing Management LLC boosted its stake in shares of Twist Bioscience by 8.4% in the 2nd quarter. Vanguard Personalized Indexing Management LLC now owns 6,031 shares of the company’s stock valued at $222,000 after purchasing an additional 469 shares in the last quarter.

Wall Street Analysts Forecast Growth

Several research analysts have recently commented on TWST shares. Barclays reduced their target price on Twist Bioscience from $45.00 to $40.00 and set an “overweight” rating on the stock in a report on Thursday, October 2nd. Evercore ISI cut their price objective on shares of Twist Bioscience from $46.00 to $42.00 and set an “outperform” rating on the stock in a report on Tuesday, October 7th. Weiss Ratings reissued a “sell (d-)” rating on shares of Twist Bioscience in a research note on Wednesday, October 8th. Finally, Cowen reaffirmed a “buy” rating on shares of Twist Bioscience in a research note on Monday, August 4th. Nine investment analysts have rated the stock with a Buy rating and two have issued a Sell rating to the company’s stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $48.56.

Twist Bioscience Company Profile

Twist Bioscience Corporation engages in the manufacture and sale of synthetic DNA-based products. The company offers synthetic genes and gene fragments used in product development for therapeutics, diagnostics, chemicals/materials, food/agriculture, data storage, and various applications within academic research by biotech, pharma, industrial chemical, and agricultural companies, as well as academic labs; Oligo pools used in targeted NGS, CRISPR gene editing, mutagenesis experiments, DNA origami, DNA computing, data storage in DNA, and other applications; and immunoglobulin G proteins for customers focused on the pursuit of drug discovery and development.